<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413516</url>
  </required_header>
  <id_info>
    <org_study_id>VIP</org_study_id>
    <nct_id>NCT01413516</nct_id>
  </id_info>
  <brief_title>Varenicline In-Patient Study</brief_title>
  <acronym>VIP</acronym>
  <official_title>A Two-Part Pilot Study of Dosing, Safety and Efficacy of Varenicline Initiated During an Acute Smoke-free Hospitalization and Continued Post-Hospitalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Investigator Initiated Research Award (IIR Award #WS981308) is a two-part pilot study
      that aims to examine acceptability and feasibility of varenicline use during an acute (72-hr)
      smoke-free hospitalization (Part 1) and 4-weeks post-hospitalization (Part 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sample will be hospitalized patients smoking at least 10 cigarettes/day prior to
      hospitalization. Intention to quit smoking will not be required for study participation.
      Using a double-blinded, placebo-controlled, randomized design, participants will receive
      varenicline (0.5 mg BID as tolerated) or placebo during their hospitalization (Part 1) and
      will continue their study medication (placebo or active drug) for 4 weeks
      post-hospitalization (Part 2). Abstinence status will be examined at 4 weeks
      post-hospitalization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7 Day Point Prevalence Abstinence From All Forms of Tobacco</measure>
    <time_frame>4 weeks after beginning study</time_frame>
    <description>Self report of being quit for 7 continuous days at the time of the 4-week follow-up survey confirmed by saliva cotinine or urine anabasine verification.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Smoking cessation counseling with placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Varenicline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Smoking cessation counseling with varenicline</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Smoking cessation counseling</intervention_name>
    <description>Counseling sessions provided by a trained smoking counselor</description>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_label>Experimental: Varenicline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill without any active medication</description>
    <arm_group_label>Placebo Control</arm_group_label>
    <other_name>sugar pill (control)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline (an approved medication for smoking cessation)</description>
    <arm_group_label>Experimental: Varenicline</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The sample, 40 women and 40 men, will be hospitalized patients recruited from Stanford
             Hospital and Clinics who report smoking at least 10 cigarettes per day prior to
             hospitalization, have confirmed tobacco use by cotinine testing, and an expected
             hospitalization of at least 3 days duration from the date of study enrollment.
             Intention to quit smoking will not be required for study participation.

        Exclusion Criteria:

        - Study exclusion criteria are: dementia or other brain injury precluding ability to
        participate; Alzheimer's Disease; Parkinson's Disease; Huntington's Disease; meningitis;
        seizure disorder of a sustained nature; delirium; brain surgery; drug and/or alcohol
        dependence; suicidal ideation; end-stage renal disease (i.e., on dialysis); hypertensive
        crisis; stroke; myocardial infarction (MI) with severe cardiac damage; pregnancy or
        breastfeeding; non-English speaking; complete homelessness; or currently engaged in tobacco
        treatment. Study staff will consult with clinical staff prior to approach for study
        enrollment. In cases of severe renal impairment (estimated creatinine clearance &lt;30
        mL/min), medical staff will consult with participants' physician to assess the
        appropriateness for study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith J Prochaska, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <results_first_submitted>February 25, 2016</results_first_submitted>
  <results_first_submitted_qc>November 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2016</results_first_posted>
  <last_update_submitted>November 4, 2017</last_update_submitted>
  <last_update_submitted_qc>November 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Judith Prochaska</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Varenicline</keyword>
  <keyword>Placebo</keyword>
  <keyword>Inpatient</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control: Sugar Pill Without Any Active Medication</title>
          <description>Smoking counseling, Placebo: Placebo comparator
Interventions:
Behavior: smoking counseling
Drug: placebo (sugar pill without any active medication)
Smoking counseling: Counseling sessions provided by a trained smoking counselor during 1st day of study along with 28 day supply of placebo
Placebo: Sugar pill without any active medication</description>
        </group>
        <group group_id="P2">
          <title>Experimental: Varenicline</title>
          <description>Smoking counseling, Varenicline: Experimental
Interventions:
Behavioral: smoking counseling
Drug: varenicline
Smoking counseling: Counseling sessions provided by trained smoking counselor during 1st day of study along with 28 day supply of varenicline
Varenicline: Varenicline (an approved medication for smoking cessation)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control: Sugar Pill Without Any Active Medication</title>
          <description>Smoking counseling, Placebo: Placebo comparator
Interventions:
Behavior: smoking counseling
Drug: placebo (sugar pill without any active medication)
Smoking counseling: Counseling sessions provided by a trained smoking counselor along with placebo during 1st day of study
Placebo: Sugar pill without any active medication</description>
        </group>
        <group group_id="B2">
          <title>Experimental: Varenicline</title>
          <description>Smoking counseling, Varenicline: Experimental
Interventions:
Behavioral: smoking counseling
Drug: varenicline
Smoking counseling: Counseling sessions provided by trained smoking counselor along with varenicline
Varenicline: Varenicline (an approved medication for smoking cessation)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="14"/>
                    <measurement group_id="B2" value="48" spread="13"/>
                    <measurement group_id="B3" value="50" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7 Day Point Prevalence Abstinence From All Forms of Tobacco</title>
        <description>Self report of being quit for 7 continuous days at the time of the 4-week follow-up survey confirmed by saliva cotinine or urine anabasine verification.</description>
        <time_frame>4 weeks after beginning study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill Without Any Active Medication</title>
            <description>Smoking counseling, Placebo: Placebo comparator
Interventions:
Behavior: smoking counseling
Drug: placebo (sugar pill without any active medication)
Smoking counseling: Counseling sessions provided by a trained smoking counselor along with placebo during 1st day of study
Placebo: Sugar pill without any active medication</description>
          </group>
          <group group_id="O2">
            <title>Experimental: Varenicline</title>
            <description>Smoking counseling, Varenicline: Experimental
Interventions:
Behavioral: smoking counseling
Drug: varenicline
Smoking counseling: Counseling sessions provided by trained smoking counselor along with varenicline
Varenicline: Varenicline (an approved medication for smoking cessation)</description>
          </group>
        </group_list>
        <measure>
          <title>7 Day Point Prevalence Abstinence From All Forms of Tobacco</title>
          <description>Self report of being quit for 7 continuous days at the time of the 4-week follow-up survey confirmed by saliva cotinine or urine anabasine verification.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>assessed by self-report at every time point</desc>
      <group_list>
        <group group_id="E1">
          <title>Control: Sugar Pill Without Any Active Medication</title>
          <description>Smoking counseling, Placebo: Placebo comparator
Interventions:
Behavior: smoking counseling
Drug: placebo (sugar pill without any active medication)
Smoking counseling: Counseling sessions provided by a trained smoking counselor during 1st day of study along with 28 day supply of placebo
Placebo: Sugar pill without any active medication</description>
        </group>
        <group group_id="E2">
          <title>Experimental: Varenicline</title>
          <description>Smoking counseling, Varenicline: Experimental
Interventions:
Behavioral: smoking counseling
Drug: varenicline
Smoking counseling: Counseling sessions provided by trained smoking counselor during 1st day of study along with 28 day supply of varenicline
Varenicline: Varenicline (an approved medication for smoking cessation)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Leg amputation</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg amputation</sub_title>
                <description>This was a planned re-hospitalization for a follow-up surgical procedure. Participant reported finishing his 4-week course of study medication on the day prior to re-hospitalization.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Renal disorder">Renal disorder</sub_title>
                <description>This adverse event occurred after the participant was scheduled to finish the 4 week course of of study medication. Participant was unable to recall whether taking study medication when the onset of the events described in the narrative occurred.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Judith Prochaska</name_or_title>
      <organization>Stanford University</organization>
      <phone>6507243608</phone>
      <email>jodi.prochaska@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

